Lapatinib and capecitabine as third-line therapy in young woman with advanced breast cancer

Lapatinib e capecitabina in III linea in donna giovane affetta da carcinoma mammario avanzato

Abstract

We report the case of a young woman with HER2-positive advanced breast cancer, arising during pregnancy, with visceral involvement at onset, treated with third line therapy with the combination lapatinib and capecitabine resulting in a nearly complete long-term tumor response . The patient had previously been treated with first line therapy with double block, pertuzumab and trastuzumab and, after disease progression, with T-DM1 resulting in a short-term stability of clinical status (Oncology).